Destiny Pharma and SporeGen® announce update from research collaboration under Innovate UK grant award to develop a biotherapeutic treatment (SPOR-COV®) for COVID-19 and Influenza
Positive results from testing SPOR-COV in several COVID-19 and influenza research models support potential as prophylactic nasal spray
Toxicology studies support safety profile
Manufacturing process established
Manufacturing and regional licensing agreement signed with HURO Biotech JSC for Vietnam
Phase 1 clinical studies completed successfully in Vietnam by HURO
Retail product based on SPOR COV technology launched in Vietnam by HURO
Partners reviewing options for next stage in development of SPOR-COV
Brighton, United Kingdom – 2nd May 2023 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today announces very encouraging results from its collaboration with SporeGen Limited (“SporeGen”), a UK biotechnology company working exclusively on Bacillus and its applications. The collaboration has been partly funded by UK Research and Innovation (UKRI) since September 2020 to co-develop SporeGen’s SPOR-COV product as a novel, preventive treatment for COVID-19, influenza and potentially other similar respiratory viral infections.
